Survival in children with relapsed/refractory acute myeloid leukemia is unsatisfactory. Treatment consists of one course of fludarabine, cytarabine and liposomal daunorubicin, followed by fludarabine and cytarabine and stem-cell transplantation. Study ITCC 020/I-BFM 2009-02 aimed to identify the recommended phase II dose of clofarabine replacing fludarabine in the abovementioned combination regimen (3+3 design). Escalating dose levels of clofarabine (20-40 mg/m2/day × 5 days) and liposomal daunorubicin (40-80 mg/m2/day) were administered with cytarabine (2 g/m2/day × 5 days). Liposomal DNR was given on day 1, 3 and 5 only. The cohort at the recommended phase II dose was expanded to make a preliminary assessment of anti-leukemic activity. Thirty-four children were enrolled: refractory 1st (n=11), early 1st (n=15), ≥2nd relapse (n=8). Dose level 3 (30 mg/m2clofarabine; 60 mg/m2liposomal daunorubicin) appeared to be safe only in patients without subclinical fungal infections. Infectious complications were dose-limiting. The recommended phase II dose was 40 mg/m2 clofarabine with 60 mg/m2 liposomal daunorubicin. Side-effects mainly consisted of infections. The overall response rate was 68% in 31 response evaluable patients, and 80% at the recommended phase II dose (n=10); 22 patients proceeded to stem cell transplantation. The 2-year probability of event-free survival (pEFS) was 26.5±7.6 and probability of survival (pOS) 32.4±8.0%. In the 21 responding patients, the 2-year pEFS was 42.9±10.8 and pOS 47.6±10.9%. Clofarabine exposure in plasma was not significantly different from that in single-agent studies. In conclusion, clofarabine was well tolerated and showed high response rates in relapsed/refractory pediatric acute myeloid leukemia. Patients with (sub) clinical fungal infections should be treated with caution. Clofarabine has been taken forward in the Berlin-Frankfurt-Münster study for newly diagnosed acute myeloid leukemia. The Study ITCC-020 was registered as EUDRA-CT 2009-009457-13; Dutch Trial Registry number 1880.

Centre for Haemato Oncology Barts Cancer Institute Queen Mary University of London UK

Children's Cancer Research Institute and St Anna Children's Hospital Department of Pediatrics Medical University of Vienna Austria

Clinical Trial Center Department of Hematology Erasmus Medical Center Rotterdam the Netherlands

Department of Pediatric Hematology and Oncology 2Faculty of Medicine Charles University Prague University Hospital Motol Czech Republic

Department of Pediatric Hematology and Oncology AP HP GH HUEP Trousseau Hospital Paris France

Department of Pediatric Hematology Robert Debré Hospital Paris France

Department of Pediatric Oncology Hematology Erasmus MC Sophia Children's Hospital Rotterdam the Netherlands Department of Pediatric Oncology Princess Máxima Center for Pediatric Oncology Utrecht the Netherlands European Consortium for Innovative Therapies for Children with Cancer Villejuif France

Department of Pediatric Oncology Hematology Erasmus MC Sophia Children's Hospital Rotterdam the Netherlands European Consortium for Innovative Therapies for Children with Cancer Villejuif France

Department of Pediatric Oncology Princess Máxima Center for Pediatric Oncology Utrecht the Netherlands Department of Pediatric Oncology VU University Medical Center Amsterdam the Netherlands 1 BFM AML committee Kiel Germany

Department of Pediatric Oncology University Children's Hospital Essen Germany

Department of Pediatric Oncology University Medical Center Groningen University of Groningen the Netherlands

Division of Pediatric Hematology and Oncology Department of Pediatrics and Adolescent Medicine University of Freiburg Germany

European Consortium for Innovative Therapies for Children with Cancer Villejuif France 1 BFM AML committee Kiel Germany

Pediatric Hematology and Oncology University Children's Hospital Münster Germany

Pediatric Hematology Department IHOP and Claude Bernard University Lyon France

Pediatric Hematology Oncology Johann Wolfgang Goethe University Frankfurt Germany

000      

00000naa a2200000 a 4500

001      

bmc19035236

003      

CZ-PrNML

005      

20191011123145.0

007      

ta

008      

191007s2018 it f 000 0|eng||

009      

AR

024    7_

$a 10.3324/haematol.2017.187153 $2 doi

035    __

$a (PubMed)29773602

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a it

100    1_

$a van Eijkelenburg, Natasha K A $u Department of Pediatric Oncology/Hematology, Erasmus MC-Sophia Children's Hospital, Rotterdam, the Netherlands. Department of Pediatric Oncology, Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands. European Consortium for Innovative Therapies for Children with Cancer (ITCC), Villejuif, France.

245    10

$a Clofarabine, high-dose cytarabine and liposomal daunorubicin in pediatric relapsed/refractory acute myeloid leukemia: a phase IB study / $c NKA. van Eijkelenburg, M. Rasche, E. Ghazaly, MN. Dworzak, T. Klingebiel, C. Rossig, G. Leverger, J. Stary, ESJM. De Bont, DA. Chitu, Y. Bertrand, B. Brethon, B. Strahm, IM. van der Sluis, GJL. Kaspers, D. Reinhardt, CM. Zwaan,

520    9_

$a Survival in children with relapsed/refractory acute myeloid leukemia is unsatisfactory. Treatment consists of one course of fludarabine, cytarabine and liposomal daunorubicin, followed by fludarabine and cytarabine and stem-cell transplantation. Study ITCC 020/I-BFM 2009-02 aimed to identify the recommended phase II dose of clofarabine replacing fludarabine in the abovementioned combination regimen (3+3 design). Escalating dose levels of clofarabine (20-40 mg/m2/day × 5 days) and liposomal daunorubicin (40-80 mg/m2/day) were administered with cytarabine (2 g/m2/day × 5 days). Liposomal DNR was given on day 1, 3 and 5 only. The cohort at the recommended phase II dose was expanded to make a preliminary assessment of anti-leukemic activity. Thirty-four children were enrolled: refractory 1st (n=11), early 1st (n=15), ≥2nd relapse (n=8). Dose level 3 (30 mg/m2clofarabine; 60 mg/m2liposomal daunorubicin) appeared to be safe only in patients without subclinical fungal infections. Infectious complications were dose-limiting. The recommended phase II dose was 40 mg/m2 clofarabine with 60 mg/m2 liposomal daunorubicin. Side-effects mainly consisted of infections. The overall response rate was 68% in 31 response evaluable patients, and 80% at the recommended phase II dose (n=10); 22 patients proceeded to stem cell transplantation. The 2-year probability of event-free survival (pEFS) was 26.5±7.6 and probability of survival (pOS) 32.4±8.0%. In the 21 responding patients, the 2-year pEFS was 42.9±10.8 and pOS 47.6±10.9%. Clofarabine exposure in plasma was not significantly different from that in single-agent studies. In conclusion, clofarabine was well tolerated and showed high response rates in relapsed/refractory pediatric acute myeloid leukemia. Patients with (sub) clinical fungal infections should be treated with caution. Clofarabine has been taken forward in the Berlin-Frankfurt-Münster study for newly diagnosed acute myeloid leukemia. The Study ITCC-020 was registered as EUDRA-CT 2009-009457-13; Dutch Trial Registry number 1880.

650    _2

$a mladiství $7 D000293

650    _2

$a protokoly antitumorózní kombinované chemoterapie $x škodlivé účinky $x terapeutické užití $7 D000971

650    _2

$a dítě $7 D002648

650    _2

$a předškolní dítě $7 D002675

650    _2

$a klofarabin $x aplikace a dávkování $x farmakokinetika $7 D000077866

650    _2

$a cytarabin $x aplikace a dávkování $x farmakokinetika $7 D003561

650    _2

$a daunomycin $x aplikace a dávkování $x farmakokinetika $7 D003630

650    _2

$a rozvrh dávkování léků $7 D004334

650    _2

$a chemorezistence $7 D019008

650    _2

$a ženské pohlaví $7 D005260

650    _2

$a lidé $7 D006801

650    _2

$a kojenec $7 D007223

650    _2

$a akutní myeloidní leukemie $x diagnóza $x farmakoterapie $x mortalita $7 D015470

650    _2

$a liposomy $7 D008081

650    _2

$a mužské pohlaví $7 D008297

650    _2

$a recidiva $7 D012008

650    _2

$a indukce remise $7 D012074

650    _2

$a opakovaná terapie $7 D019233

650    _2

$a analýza přežití $7 D016019

650    _2

$a výsledek terapie $7 D016896

650    _2

$a mladý dospělý $7 D055815

655    _2

$a klinické zkoušky, fáze I $7 D017426

655    _2

$a časopisecké články $7 D016428

655    _2

$a práce podpořená grantem $7 D013485

700    1_

$a Rasche, Mareike $u Department of Pediatric Oncology, University Children's Hospital, Essen, Germany.

700    1_

$a Ghazaly, Essam $u Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, UK.

700    1_

$a Dworzak, Michael N $u Children's Cancer Research Institute and St. Anna Children's Hospital, Department of Pediatrics, Medical University of Vienna, Austria.

700    1_

$a Klingebiel, Thomas $u Pediatric Hematology/Oncology, Johann Wolfgang Goethe University, Frankfurt, Germany.

700    1_

$a Rossig, Claudia $u Pediatric Hematology and Oncology, University Children's Hospital, Münster, Germany.

700    1_

$a Leverger, Guy $u Department of Pediatric Hematology and Oncology, AP-HP, GH HUEP, Trousseau Hospital, Paris, France.

700    1_

$a Stary, Jan $u Department of Pediatric Hematology and Oncology, 2Faculty of Medicine, Charles University Prague, University Hospital Motol, Czech Republic.

700    1_

$a De Bont, Eveline S J M $u Department of Pediatric Oncology, University Medical Center Groningen, University of Groningen, the Netherlands.

700    1_

$a Chitu, Dana A $u Clinical Trial Center, Department of Hematology, Erasmus Medical Center, Rotterdam, the Netherlands.

700    1_

$a Bertrand, Yves $u Pediatric Hematology Department, IHOP and Claude Bernard University, Lyon, France.

700    1_

$a Brethon, Benoit $u Department of Pediatric Hematology, Robert Debré Hospital, Paris, France.

700    1_

$a Strahm, Brigitte $u Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, University of Freiburg, Germany.

700    1_

$a van der Sluis, Inge M $u Department of Pediatric Oncology/Hematology, Erasmus MC-Sophia Children's Hospital, Rotterdam, the Netherlands. European Consortium for Innovative Therapies for Children with Cancer (ITCC), Villejuif, France.

700    1_

$a Kaspers, Gertjan J L $u Department of Pediatric Oncology, Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands. Department of Pediatric Oncology, VU University Medical Center, Amsterdam, the Netherlands. I-BFM-AML committee, Kiel, Germany.

700    1_

$a Reinhardt, Dirk $u European Consortium for Innovative Therapies for Children with Cancer (ITCC), Villejuif, France. I-BFM-AML committee, Kiel, Germany.

700    1_

$a Zwaan, C Michel $u Department of Pediatric Oncology/Hematology, Erasmus MC-Sophia Children's Hospital, Rotterdam, the Netherlands c.m.zwaan@erasmusmc.nl. Department of Pediatric Oncology, Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands. European Consortium for Innovative Therapies for Children with Cancer (ITCC), Villejuif, France.

773    0_

$w MED00001963 $t Haematologica $x 1592-8721 $g Roč. 103, č. 9 (2018), s. 1484-1492

856    41

$u https://pubmed.ncbi.nlm.nih.gov/29773602 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y a $z 0

990    __

$a 20191007 $b ABA008

991    __

$a 20191011123605 $b ABA008

999    __

$a ok $b bmc $g 1451896 $s 1073786

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2018 $b 103 $c 9 $d 1484-1492 $e 20180517 $i 1592-8721 $m Haematologica $n Haematologica $x MED00001963

LZP    __

$a Pubmed-20191007